History suggests Nvidia should modestly beat Eli Lilly over the next roughly two months,” notes a DataTrek analyst — but ...

Very few investors can match Stanley Druckenmiller. He delivered an average annual return of over 30% over three decades at ...

The City of Huntsville has taken another step toward bringing pharmaceutical giant Eli Lilly’s $6 billion facility to the ...

It doesn't have the highest yield, but it has enviable dividend coverage and a long history of surviving in a competitive ...

Explore Pfizer Inc.’s 2025-2026 outlook: challenges, flat revenues, patent risks, and potential from the Metsera deal. Click ...

VanEck Pharmaceutical ETF is rated a Buy with stability, earnings visibility, and resilience across volatile market cycles.

Shares have corrected 55.8 per cent from their high earlier this year of $423.32 to $187.01 based on the Dec. 11 closing ...

Agentforce Life Sciences platform continues to gain momentum across the healthcare industry. Recently, Novartis ($NVS) ...